ISARIC - Coronavirus Clinical Characterisation Consortium (ISARIC-4C)

Grant number: MC_PC_19025

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $98,958.45
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    Dr. J Kenneth Baillie
  • Research Location

    United Kingdom
  • Lead Research Institution

    University of Edinburgh
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    Data Management and Data Sharing

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

This award is being made in support of urgent research costs to enable sampling amongst UK COVID-19 cases. This is essential in developing diagnostics, therapeutics (monoclonal antibodies) and understanding the pathogen and the natural history of the disease, as well as developing rapid prognostic tools. This funding support will ensure samples are distributed safely to researchers. Research could change the course of the rapidly spreading outbreak.

Publicationslinked via Europe PMC

Evaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severity.

Patient emergency health-care use before hospital admission for COVID-19 and long-term outcomes in Scotland: a national cohort study.

CAGE sequencing reveals CFTR-dependent dysregulation of type I IFN signaling in activated cystic fibrosis macrophages.

Adeno-associated virus 2 infection in children with non-A-E hepatitis.

Neurological manifestations of COVID-19 in adults and children.

Variation in ERAP2 has opposing effects on severe respiratory infection and autoimmune disease.

Estimating distribution of length of stay in a multi-state model conditional on the pathway, with an application to patients hospitalised with Covid-19.

Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study.

Comorbidities, multimorbidity and COVID-19.